Fruquintinib Combined With mFOLFOX6/FOLFIRI in First-line Treatment for Metastatic Colorectal Cancer HCCSC C02 Trial

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fruquintinib (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
Indications Colorectal cancer
Focus Therapeutic Use

04 Jun 2024 Status changed from recruiting to completed, according to a Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
24 Oct 2023 Updated results (n=37; cutoff: April 20, 2023) assessing the efficacy and safety of fruquintinib plus mFOLFOX6/FOLFIRI in advanced metastatic colorectal cancer, presented at the 48th European Society for Medical Oncology Congress.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com